Very interesting. He is delivering this in bite sized chunks but has at least now linked it to AMBS indirectly and is calling out the specific strategy in regard to MANF. Risk mentioned that he talks to Fumi all the time. My assumption is Gerald contributes to, and is fully aware, of these blogs before they are sent. No matter how far away a treatment might be for Wolframs/Diabetes, the mere mention of data with a real possibility of a treatment is monumental for the AMBS share price. Throw in an orphan designation and a partner and the price won't look back. Also, keep in mind they can get orphan designation for Type 1 Diabetes as well. This is a point that should not be forgotten.